1、Q1 2025 ResultsConference call and webcast for investors and analysts 29 April 20252Forward-looking statementsThis document contains certain forward-looking statements with respect to the operations,performance and financial condition of the Group,including,among other things,statements about expect

2、ed revenues,margins,earnings per share or other financial or other measures.Although the Group believes its expectations are based on reasonable assumptions,any forward-looking statements,by their very nature,involve risks and uncertainties and may be influenced by factors that could cause actual ou

3、tcomes and results to be materially different from those predicted.The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements.The Group identifies the forward

4、-looking statements by using the words anticipates,believes,expects,intends and similar expressions in such statements.Important factors that could cause actual results to differ materially from those contained in forward-looking statements,certain of which are beyond the Groups control,include,amon

5、g other things:the risk of failure or delay in delivery of pipeline or launch of new medicines;the risk of failure to meet regulatory or ethical requirements for medicine development or approval;the risk of failures or delays in the quality or execution of the Groups commercial strategies;the risk o

6、f pricing,affordability,access and competitive pressures;the risk of failure to maintain supply of compliant,quality medicines;the risk of illegal trade in the Groups medicines;the impact of reliance on third-party goods and services;the risk of failure in information technology or cybersecurity;the